NCT02788461View on ClinicalTrials.gov

Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Non-Small Cell Lung Cancer
Interventions
RADIATION

Chemoradiotherapy

Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.

RADIATION

Chemoradiotherapy with Integrated Boost Dose

Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.

Trial Locations (7)

K7L 2V7

Kingston General Hospital, Kingston

N6A 4L6

London Regional Cancer Program, London

L3Y 2P9

Stronach Regional Cancer Centre at Southlake Regional Health Centre, Newmarket

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H4A 3J1

McGill University Health Centre, Glen site Cedars Cancer Center, Montreal

G2L 2Z3

CHU de Quebec - L'Hôtel-Dieu de Québec, Québec

J1H 5N4

CHUS - Hôpital Fleurimont, Sherbrooke

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02788461 - Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy | Biotech Hunter | Biotech Hunter